Comparative Pharmacology
Head-to-head clinical analysis: ATROVENT HFA versus INCRUSE ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROVENT HFA versus INCRUSE ELLIPTA.
ATROVENT HFA vs INCRUSE ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist of muscarinic acetylcholine receptors (M1-M3), blocking acetylcholine-mediated bronchoconstriction and mucus secretion in airways.
Umeclidinium is a long-acting muscarinic antagonist (LAMA). It competitively inhibits M3 muscarinic receptors in the airways, reducing acetylcholine-induced bronchoconstriction and mucus secretion.
2 inhalations (34 mcg per inhalation) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
Inhalation: 1 inhalation (62.5 mcg umeclidinium) once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours. Clinically, bronchodilation persists longer due to local retention in the airways.
Terminal elimination half-life is approximately 11 hours (range 10–13 hours) after inhalation, supporting once-daily dosing.
Renal (70% as unchanged drug and metabolites), fecal (20% as metabolites, primarily via biliary excretion).
Umeclidinium is eliminated primarily by hepatic metabolism and biliary excretion; after oral administration, approximately 58% of the dose is excreted in feces (mostly as parent drug) and about 22% in urine. Renal excretion of unchanged drug is minimal (<1%).
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator